Adamax Clinical Protocol Guide — Peptide Protocol Portal

Adamax

N-Acetyl Semax Analog with Adamantyl Group — Synthetic Nootropic Neuropeptide / ACTH(4–10) Analog / Advanced Semax Derivative

Intended Audience: Licensed physicians and advanced practitioners integrating neurotrophic peptides, cognitive modulators, and central metabolic regulators into clinical practice. This guide is particularly suited for those managing patients with cognitive fatigue, neuroendocrine dysregulation, stress-related metabolic resistance, or individuals pursuing high-performance cognitive enhancement alongside body composition and metabolic health goals.

1. Clinical Overview of Adamax

Molecule:
Adamax (N-Acetyl Semax analog with adamantyl group)

Classification:
Synthetic nootropic neuropeptide • ACTH(4–10) analog • Advanced Semax derivative • Cognitive optimizer

Clinical Orientation

Adamax is an advanced derivative of the well-studied peptide Semax, structurally enhanced with an adamantyl group and N-terminal acetylation to improve central nervous system penetration and metabolic stability. Designed to elevate neuroplasticity, improve focus, and protect against oxidative brain injury, Adamax is considered a high-potency cognitive optimizer with promising nootropic and neuroprotective effects.

Key Advantages Over Semax:

Enhanced CNS penetration via adamantyl modification
Improved metabolic stability from N-terminal acetylation
Higher potency at lower doses
Extended duration of action

Research-Supported Applications

Research and practitioner reports suggest Adamax may be used to support:

Memory, focus, and executive function
Resilience to stress and cognitive fatigue
Neuroplasticity and synaptic function
Post-injury or post-inflammatory brain recovery
Brain aging and mitochondrial health

2. Mechanism of Action

Adamax exerts its effects through multiple neurotrophic and neuromodulatory pathways:

Primary Mechanisms:

Upregulates BDNF (brain-derived neurotrophic factor) and other neurotrophins
Enhances synaptic plasticity and LTP (long-term potentiation)
Increases dopaminergic and serotonergic tone for mood and motivation
Stabilizes mitochondrial function and reduces oxidative stress
Modulates pro-inflammatory cytokines and neuroimmune pathways

Neurotrophic Cascade

By activating BDNF and related growth factors, Adamax supports:

Neuronal survival and differentiation
Dendritic branching and spine formation
Synaptic strengthening and memory consolidation
Hippocampal and cortical plasticity

3. Potential Clinical Benefits

Cognitive Enhancement

Enhanced attention, learning, and working memory
Improved focus without stimulant side effects
Better executive function and decision-making
Reduced mental fatigue during prolonged cognitive tasks

Stress Resilience & Mood

Improved emotional regulation under stress
Non-stimulant mental energy and mood stability
Anxiolytic properties without sedation

Neuroprotection

Neuroprotection post-TBI or ischemia (preclinical models)
Reduced neuroinflammation and cognitive decline
Support for brain aging and mitochondrial health

4. Route of Administration

Route	Preference	Notes
Intranasal	Preferred	Direct CNS targeting, rapid onset, bypasses BBB
Subcutaneous	Alternative	Systemic delivery, reliable absorption

5. Dosing Guidelines

Intranasal Protocol (Preferred)

Standard Intranasal Dosing:

Starting dose: 100 mcg per nostril (200 mcg total), once or twice daily
Optional: Midday microdose for cognitive endurance
Concentration: 1 mg/mL; spray volume ~0.1 mL per actuation
Cycling: 5 days on / 2 days off OR 10 days on / 4 days off
Washout: Every 6–8 weeks as needed

Subcutaneous Protocol (Alternative)

Reconstitution & Dosing:

Reconstitution: 10 mg vial with 2 mL bacteriostatic saline → 5 mg/mL
Starting dose: 100–200 mcg SC daily or every other day
Maximum: 500 mcg/day in divided doses
Monitoring: Subjective response and tolerability

💡 Clinical Tip: Most practitioners find intranasal administration provides faster onset and more pronounced cognitive effects due to direct CNS delivery. Reserve subcutaneous for patients who cannot tolerate intranasal or when systemic effects are preferred.

6. Treatment Archetypes — Who Is This For?

High-Performance Cognitive Optimization

Students, executives, creatives, and professionals requiring sustained focus and mental clarity.

Protocol: 200 mcg intranasal AM, optional 100 mcg midday microdose

Post-TBI or Neurologic Insult Recovery

Patients recovering from traumatic brain injury, stroke, or neuroinflammatory conditions.

Protocol: 200–400 mcg daily (divided doses), combined with SS-31 and NAD+

Age-Related Cognitive Support

Memory and cognition support in aging populations experiencing mild cognitive decline.

Protocol: 200 mcg intranasal daily, cycling 5/2, with Pinealon for genomic stability

Neurodiverse Focus Enhancement

Focus and learning enhancement in neurodiverse profiles (ADHD-like presentations) seeking non-stimulant options.

Protocol: Start 100 mcg, titrate to response, combine with Selank for mood balance

Nootropic & Neuroregenerative Programs

Adjunctive support in comprehensive cognitive optimization and biohacking protocols.

Protocol: Stack with Selank, Pinealon, NAD+, and mitochondrial support agents

7. Synergistic Stacking Options

Adamax + Selank

Mood balancing and executive function synergy; anxiolytic + cognitive enhancement

Adamax + Pinealon

Anti-aging and genomic neurostability; epigenetic brain health support

Adamax + SS-31

Mitochondrial support and neuroinflammation reduction; cellular energy optimization

Adamax + NAD+

Energy metabolism and neuroprotective enhancement; sirtuin activation

Adamax + DSIP

Sleep optimization adjunct to support cognitive recovery and memory consolidation

Adamax + Dihexa

Synergistic neuroplasticity and memory enhancement; advanced cognitive stack

8. Contraindications & Cautions

Contraindications:

Active bipolar disorder or manic episodes
Uncontrolled seizure disorders
Pregnancy, lactation, pediatric use (not studied)

Use With Caution:

Concurrent stimulant or dopaminergic medications
History of anxiety or panic disorders (start low, titrate slowly)
Patients on MAOIs or serotonergic medications

9. Monitoring Parameters

Subjective Monitoring

Mood, energy, and cognitive performance
Sleep patterns and sleep quality
Stress resilience and emotional regulation
Focus, memory, and mental clarity metrics

Optional Objective Measures

Cognitive testing (MoCA, computerized cognitive batteries)
EEG or qEEG mapping in research/advanced clinical settings
Heart rate variability (HRV) for stress response

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Adamax and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Adamax Clinical Reference Guide

1. Panchenko, S.A., et al. (2017). Neuroprotective and Nootropic Properties of ACTH Analog Semax and Its Derivatives. Neuroscience and Behavioral Physiology, 47(5), 567–575.

2. Myasoedov, N.F., et al. (2019). Peptide-Based Neurotrophic Agents: Advances in Semax and Selank Development. Neurochemical Journal, 13(4), 261–271.

3. Jay Campbell. (2025). Adamax and P21: The Next Evolution in Cognitive Peptides. Optimized Biohacking Review, accessed March 2025.

4. Behemoth Labz. (2025). Adamax Research Profile. Available at: https://www.behemothlabz.com

5. Cytokine & Growth Factor Reviews. (2017). Mechanisms of BDNF Modulation via Semax.

6. PatSnap Synapse. (2024). Peptide Derivative Analysis – N-Acetyl Semax vs. Adamax. Available at: https://www.patsnap.com

7. Peptide Protocol Portal Internal Monograph Archive. (2025).

Adamax (N-Acetyl Semax Analog)